tiprankstipranks
Trending News
More News >

Inozyme downgraded to Hold from Buy at Needham

Needham analyst Joseph Stringer downgraded Inozyme (INZY) to Hold from Buy without a price target after BioMarin Pharmaceutical (BMRN) announced a definitive agreement to acquire the company for $4.00 per share in cash.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1